Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Oct 5, 2019 in Prostate cancer | 0 comments

In a nutshell

This study aimed to evaluate the use of high-intensity focal ultrasound (HIFU) for the treatment of localized prostate cancer. This study found that HIFU is a safe treatment with good oncological results and minimal side-effects. 

Some background

High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses ultrasonic waves to heat tissue. It can be used to treat prostate cancer (PCa). It can remove the whole prostate gland or just a part of it.

The outcomes of this treatment for localized prostate cancer are still under investigation. 

Methods & findings

This study included 107 patients who underwent HIFU. 88% had intermediate/high-risk disease. 54% of the patients had removal of half the prostate. 9% had removal of the cancer only and 40% had a removal of a quarter of the prostate. They were followed up for an average of 30 months. The average pre-surgery PSA was 7.7. PSA is a prostate-specific antigen. It is a marker in the blood used to monitor PCa. 

After surgery, PSA dropped an average of 71%. 8% had a biochemical recurrence (rise of PSA levels) and 11% required additional treatment. 85.5% of patients did not require additional procedures after HIFU. 

Side-effects from this treatment included 1% new use of pads and 14% new erectile dysfunction. 

The bottom line

This study found that HIFU has good oncological results and minimal side-effects for the partial ablation of localized prostate cancer. 

The fine print

This study had a selected group of patients from a single medical center. These results may not apply to all patients. Further studies are needed.

Published By :


Date :

Aug 23, 2019

Original Title :

Focal high-intensity focussed ultrasound partial gland ablation for the treatment of localised prostate cancer: a report of medium-term outcomes from a single-centre in the United Kingdom.

click here to get personalized updates